Paride Fenaroli1,2, Federica Maritati3, Augusto Vaglio4,5,6. 1. Nephrology Unit, University Hospital, Parma, Italy. 2. Renal Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Nephrology, Dialysis and Kidney Transplant Unit, Ospedali Riuniti, Ancona, Italy. 4. Department of Biomedical, Experimental and Clinical Sciences "Mario Serio", University of Firenze, Florence, Italy. augusto.vaglio@unifi.it. 5. Dipartimento di Scienze Biomediche Sperimentali e Cliniche "Mario Serio", Università di Firenze, Viale Pieraccini, 6, 50139, Florence, Italy. augusto.vaglio@unifi.it. 6. Nephrology and Dialysis Unit, Meyer Children's Hospital, Florence, Italy. augusto.vaglio@unifi.it.
Abstract
PURPOSE OF THE REVIEW: We aim to review the most relevant diagnostic features and treatment options of retroperitoneal fibrosis, in order to provide a useful guide for clinical practice. RECENT FINDINGS: The recent literature highlights the role of imaging studies such as computed tomography, magnetic resonance imaging and positron emission tomography as useful tools for the diagnosis of retroperitoneal fibrosis, with retroperitoneal biopsy being reserved to atypical cases. The treatment approach is mainly conservative and is based on the use of medical therapies plus urological interventions. Medical therapies essentially comprise glucocorticoids and immunosuppressants-either traditional or biological agents such as rituximab. Surgical ureterolysis is only left for refractory cases. Recent findings in retroperitoneal fibrosis highlight the possibility of a non-invasive diagnostic approach and a conservative treatment strategy.
PURPOSE OF THE REVIEW: We aim to review the most relevant diagnostic features and treatment options of retroperitoneal fibrosis, in order to provide a useful guide for clinical practice. RECENT FINDINGS: The recent literature highlights the role of imaging studies such as computed tomography, magnetic resonance imaging and positron emission tomography as useful tools for the diagnosis of retroperitoneal fibrosis, with retroperitoneal biopsy being reserved to atypical cases. The treatment approach is mainly conservative and is based on the use of medical therapies plus urological interventions. Medical therapies essentially comprise glucocorticoids and immunosuppressants-either traditional or biological agents such as rituximab. Surgical ureterolysis is only left for refractory cases. Recent findings in retroperitoneal fibrosis highlight the possibility of a non-invasive diagnostic approach and a conservative treatment strategy.
Authors: D Corradi; R Maestri; A Palmisano; S Bosio; P Greco; L Manenti; S Ferretti; R Cobelli; G Moroni; A P Dei Tos; C Buzio; A Vaglio Journal: Kidney Int Date: 2007-07-11 Impact factor: 10.612
Authors: Augusto Vaglio; Maria G Catanoso; Lucia Spaggiari; Luca Magnani; Nicolò Pipitone; Pierluigi Macchioni; Lia Pulsatelli; Maria Nicastro; Gabriella Becchi; Domenico Corradi; Annibale Versari; Luigi Boiardi; Carlo Salvarani Journal: Arthritis Rheum Date: 2013-09